uniQure Prices Public Offering at $45.50 per Share, Raising $225 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 hours ago
0mins
Source: Newsfilter
- Offering Pricing: uniQure announced the pricing of its public offering at $45.50 per share for 4,945,055 ordinary shares, expecting gross proceeds of approximately $225 million, which will significantly bolster funding for its R&D and market expansion efforts.
- Underwriter Arrangement: The offering is managed by Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets, reflecting strong market confidence in uniQure and robust demand for its gene therapy products.
- Additional Share Option: uniQure granted underwriters a 30-day option to purchase up to 741,758 additional ordinary shares at the same public offering price, providing the company with added financial flexibility for future initiatives.
- Market Outlook: The offering is expected to close on June 25, 2026, and if successful, will provide uniQure with a solid financial foundation to continue its innovations and enhance its competitive position in the gene therapy sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy QURE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on QURE
Wall Street analysts forecast QURE stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 44.390
Low
33.00
Averages
49.88
High
70.00
Current: 44.390
Low
33.00
Averages
49.88
High
70.00
About QURE
Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
uniQure Prices Public Offering at $45.50 per Share, Raising $225 Million
- Offering Pricing: uniQure announced the pricing of its public offering at $45.50 per share for 4,945,055 ordinary shares, expecting gross proceeds of approximately $225 million, which will significantly bolster funding for its R&D and market expansion efforts.
- Underwriter Arrangement: The offering is managed by Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets, reflecting strong market confidence in uniQure and robust demand for its gene therapy products.
- Additional Share Option: uniQure granted underwriters a 30-day option to purchase up to 741,758 additional ordinary shares at the same public offering price, providing the company with added financial flexibility for future initiatives.
- Market Outlook: The offering is expected to close on June 25, 2026, and if successful, will provide uniQure with a solid financial foundation to continue its innovations and enhance its competitive position in the gene therapy sector.
See More
uniQure Proposes $150 Million Public Offering to Strengthen Balance Sheet
- Funding Initiative: uniQure N.V. has proposed a $150 million public offering aimed at strengthening its balance sheet and supporting ongoing development programs, indicating the company's proactive stance towards future growth.
- Securities Issuance Details: The offering will include ordinary shares and pre-funded warrants for certain investors, with all securities sold by the company, ensuring that funds directly support its strategic objectives.
- Underwriter Arrangement: Leerink Partners and Stifel are serving as joint bookrunning managers for the offering, highlighting the professional backing in capital markets and enhancing investor confidence in the offering's success.
- Market Condition Impact: uniQure noted that the offering remains subject to market conditions, with no assurance regarding its timing, size, or completion, reflecting the uncertainty in the current market environment that may affect the financing plan.
See More
uniQure Launches $150M Underwritten Public Offering
- Offering Size: uniQure has announced a $150 million underwritten public offering, intending to issue ordinary shares and pre-funded warrants to certain investors, indicating a significant capital market financing need for the company.
- Market Reaction: Following the announcement, uniQure's shares slipped nearly 3% in after-hours trading, reflecting investor caution regarding the offering, which may impact the company's short-term market performance.
- Underwriting Arrangement: All securities in the offering will be issued by uniQure, and the company plans to grant underwriters a 30-day option to purchase up to an additional $22.5 million of ordinary shares on the same terms, enhancing the offering's flexibility.
- Underwriter Role: Leerink Partners and Stifel have been appointed as bookrunning managers for the offering, indicating the company's professionalism and market trust in selecting underwriters, which may help improve the offering's success rate.
See More
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
uniQure Releases Initial Data on Gene Therapy AMT-260
- Clinical Trial Progress: uniQure's Phase I/IIa trial of AMT-260 shows that three out of six patients achieved a 79% to 100% reduction in seizures over four to six months, indicating potential therapeutic efficacy for refractory mesial temporal lobe epilepsy.
- Safety Profile: As of the May 29, 2026 data cutoff, no serious adverse events were reported for AMT-260, with all adverse events classified as mild or moderate, primarily headaches (N=2), providing a solid safety foundation for future clinical applications.
- Ongoing Research Plans: Enrollment for a second higher-dose cohort is ongoing, expected to complete by mid-2026, with plans to present updated results in the first half of 2027, reflecting the company's continued confidence in the therapy's potential.
- Significant Market Potential: With approximately 300,000 refractory temporal lobe epilepsy patients in the U.S., the development of AMT-260 not only offers a new treatment option but also opens new market opportunities in the gene therapy sector, further solidifying uniQure's leadership in the industry.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
uniQure Prices Public Offering at $45.50 per Share, Raising $225 Million
- Offering Pricing: uniQure announced the pricing of its public offering at $45.50 per share for 4,945,055 ordinary shares, expecting gross proceeds of approximately $225 million, which will significantly bolster funding for its R&D and market expansion efforts.
- Underwriter Arrangement: The offering is managed by Leerink Partners, Stifel, Guggenheim Securities, and RBC Capital Markets, reflecting strong market confidence in uniQure and robust demand for its gene therapy products.
- Additional Share Option: uniQure granted underwriters a 30-day option to purchase up to 741,758 additional ordinary shares at the same public offering price, providing the company with added financial flexibility for future initiatives.
- Market Outlook: The offering is expected to close on June 25, 2026, and if successful, will provide uniQure with a solid financial foundation to continue its innovations and enhance its competitive position in the gene therapy sector.
See More
uniQure Proposes $150 Million Public Offering to Strengthen Balance Sheet
- Funding Initiative: uniQure N.V. has proposed a $150 million public offering aimed at strengthening its balance sheet and supporting ongoing development programs, indicating the company's proactive stance towards future growth.
- Securities Issuance Details: The offering will include ordinary shares and pre-funded warrants for certain investors, with all securities sold by the company, ensuring that funds directly support its strategic objectives.
- Underwriter Arrangement: Leerink Partners and Stifel are serving as joint bookrunning managers for the offering, highlighting the professional backing in capital markets and enhancing investor confidence in the offering's success.
- Market Condition Impact: uniQure noted that the offering remains subject to market conditions, with no assurance regarding its timing, size, or completion, reflecting the uncertainty in the current market environment that may affect the financing plan.
See More
uniQure Launches $150M Underwritten Public Offering
- Offering Size: uniQure has announced a $150 million underwritten public offering, intending to issue ordinary shares and pre-funded warrants to certain investors, indicating a significant capital market financing need for the company.
- Market Reaction: Following the announcement, uniQure's shares slipped nearly 3% in after-hours trading, reflecting investor caution regarding the offering, which may impact the company's short-term market performance.
- Underwriting Arrangement: All securities in the offering will be issued by uniQure, and the company plans to grant underwriters a 30-day option to purchase up to an additional $22.5 million of ordinary shares on the same terms, enhancing the offering's flexibility.
- Underwriter Role: Leerink Partners and Stifel have been appointed as bookrunning managers for the offering, indicating the company's professionalism and market trust in selecting underwriters, which may help improve the offering's success rate.
See More
uniQure Achieves Major Regulatory Milestone for Gene Therapy
- Stock Surge: uniQure's shares soared 78.4% on June 17 following the announcement of a major regulatory milestone for AMT-130, although a 3.9% drop on June 18 indicates some volatility; overall, investor confidence in the therapy appears to be strengthening.
- FDA Meeting Outcomes: During a recent Type B meeting, the FDA confirmed that three-year data from the AMT-130 study could serve as the primary basis for a Biologics License Application (BLA), which is expected to be filed in Q3 2026, potentially accelerating market access for the therapy.
- Clinical Trial Design Adjustments: The FDA has requested that uniQure align on the confirmatory study design before BLA submission, including the consideration of a standard-of-care control group, which will impact future clinical trial strategies and timelines.
- Significant Market Potential: As the first therapy for Huntington's disease to receive FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, AMT-130's potential approval could significantly enhance uniQure's market position, addressing a substantial unmet need in Huntington's disease treatment and presenting considerable commercial opportunities for the company.
See More
uniQure Releases Initial Data on Gene Therapy AMT-260
- Clinical Trial Progress: uniQure's Phase I/IIa trial of AMT-260 shows that three out of six patients achieved a 79% to 100% reduction in seizures over four to six months, indicating potential therapeutic efficacy for refractory mesial temporal lobe epilepsy.
- Safety Profile: As of the May 29, 2026 data cutoff, no serious adverse events were reported for AMT-260, with all adverse events classified as mild or moderate, primarily headaches (N=2), providing a solid safety foundation for future clinical applications.
- Ongoing Research Plans: Enrollment for a second higher-dose cohort is ongoing, expected to complete by mid-2026, with plans to present updated results in the first half of 2027, reflecting the company's continued confidence in the therapy's potential.
- Significant Market Potential: With approximately 300,000 refractory temporal lobe epilepsy patients in the U.S., the development of AMT-260 not only offers a new treatment option but also opens new market opportunities in the gene therapy sector, further solidifying uniQure's leadership in the industry.
See More
Latest Wall Street Rating Updates
- Apple Rating Reaffirmed: Bank of America reiterates Apple as a buy, believing that price increases are already reflected in the stock, anticipating that rising memory costs will force Apple to raise prices, impacting future earnings performance.
- Nice Upgrade: DA Davidson upgrades Nice from neutral to buy, maintaining a $110 price target, arguing that concerns about AI disruption are overblown, suggesting a more optimistic outlook that could boost the company's stock price.
- Immix Biopharma Initiation: Bank of America initiates coverage of Immix Biopharma with a buy rating and a $27 price target, citing the company's differentiated product offerings as a significant growth driver.
- Salesforce Upgrade: Monness Crespi Hardt upgrades Salesforce from neutral to buy with a $200 price target, based on its depressed valuation, strong cash flow generation, and support for customer transformation, which are expected to drive stock price increases.
See More
